The Australian government has approved the sale of the first GLP-1 receptor agonist weight loss drugs in tablet form. The medication, which includes semaglutide and tirzepatide, is expected to be available in pharmacies across the country by early 2025. These drugs are designed to help patients manage weight by mimicking the action of incretin hormones, which regulate blood sugar and appetite.

The approval comes after extensive clinical trials and regulatory review by the Therapeutic Goods Administration. Health officials say the drugs offer a new option for individuals struggling with obesity, particularly those who have not responded to traditional weight loss methods. The tablets are intended for use in conjunction with lifestyle changes, including diet and exercise.

GLP-1 drugs have gained attention globally for their effectiveness in weight management and diabetes treatment. In Australia, the rise in obesity rates has prompted increased interest in innovative medical solutions. The introduction of these tablets marks a significant shift in the country’s approach to weight-related health issues, offering a more accessible and convenient alternative to injectable forms of the medication.